Abstract
Objective: To evaluate tuberculosis treatment efficiency depending on the combination of isoforms of allelic variants of genes GSTM1 and GSTT1 and on the resistance profile.
Methods: We have examined 100 patients with newly diagnosed TB (NDTB) and with multidrug-resistant TB (MDR-TB). Polymorphism GSTM1 areas were isolated using complex multi PCR for M. Arana et all (1996).
Results: Patients with sensitive pulmonary NDTB who are carriers of the wild alleles (GSTM1 + / GSTT1 +) experienced the bacterioexcretion termination more frequently with the 60thdose (by18,40%; (χ² = 3,59, p = 0,052)); in MDR-TB the negative sputum microscopy was recorded more frequently with the 120/240th doses (by 45.64% (p=0.002)), respectively. With null genotype in haplotypes, the frequency of bacterioexcretionat a dose of 60 was lower by 47,23% (χ² = 18,67, p < 0.001) with a high probability of the forecast for ineffective treatment of sensitive NDTB, while in MRD-TB the bacterioexcretion stopped in 66.67% of people more frequently with higher doses of drugs (240).
Conclusions: The deletion in the promotive area of both genes (GSTT10 / 0 / GSTM10 / 0) increases the risk of no effect of antituberculosis therapy resulting from the cessation of bacterioexcretion by 16.67 times [OR = 24,50, 95% CI OR: 2,18-142 64, p = 0.009]. The presence of mutant isoform GSTM1 genotype in haplotype (GSTT1 + / GSTM10 / 0) reduces the chances of effective treatment, which is the lowest with the 60th dose inNDTBand the 240th dose in MDR-TB [OR=0,07, 95%CIOR: 0,09-0,57, p=0,002 andOR=0,37, 95%CIOR: 0,14-0,97, p=0,04].
- Copyright ©the authors 2016
